litlas
ログインアカウント作成

Timothy A. Yap

2007–2025 年に発表

177
論文数
25,122
被引用数
78
h 指数
160
i10 指数

被引用数

Timothy A. Yap の年別被引用数1896 年: 被引用 1 件1995 年: 被引用 1 件1999 年: 被引用 1 件2007 年: 被引用 2 件2008 年: 被引用 30 件2009 年: 被引用 84 件2010 年: 被引用 230 件2011 年: 被引用 270 件2012 年: 被引用 279 件2013 年: 被引用 268 件2014 年: 被引用 284 件2015 年: 被引用 235 件2016 年: 被引用 275 件2017 年: 被引用 224 件2018 年: 被引用 208 件2019 年: 被引用 834 件2020 年: 被引用 1,011 件2021 年: 被引用 1,142 件2022 年: 被引用 1,063 件2023 年: 被引用 946 件2024 年: 被引用 1,526 件2025 年: 被引用 892 件2026 年: 被引用 28 件1897〜1994 年は被引用が無いため表示していません1996〜1998 年は被引用が無いため表示していません2000〜2006 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,431 件、この内訳の 25.8%中国: 引用元論文 1,875 件、この内訳の 14.1%イギリス: 引用元論文 1,168 件、この内訳の 8.8%イタリア: 引用元論文 670 件、この内訳の 5%ドイツ: 引用元論文 540 件、この内訳の 4.1%フランス: 引用元論文 481 件、この内訳の 3.6%カナダ: 引用元論文 474 件、この内訳の 3.6%スペイン: 引用元論文 419 件、この内訳の 3.1%オーストラリア: 引用元論文 326 件、この内訳の 2.5%オランダ: 引用元論文 322 件、この内訳の 2.4%日本: 引用元論文 295 件、この内訳の 2.2%スイス: 引用元論文 284 件、この内訳の 2.1%
0%25.8%その他 22.7%

機関

分野

  • Medicine50.4%
  • Biochemistry, Genetics and Molecular Biology39.9%
  • Immunology and Microbiology3.9%
  • Computer Science1%
  • Engineering0.8%
  • Materials Science0.8%
  • その他3.2%

トピック

  • PARP inhibition in cancer therapy7.5%
  • DNA Repair Mechanisms5.4%
  • Cancer Genomics and Diagnostics3.6%
  • Cancer Immunotherapy and Biomarkers2.8%
  • PI3K/AKT/mTOR signaling in cancer2.6%
  • Prostate Cancer Treatment and Research2%
  • その他76.1%

共著者

全論文

検索で開く
  1. State-of-the-art strategies for targeting the DNA damage response in cancer

    著者: Patrick G. Pilié, Chad Tang, Gordon B. Mills, Timothy A. Yap - Nature Reviews Clinical Oncology 2018 被引用: 1,197

  2. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

    著者: Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam, Hagop M. Kantarjian, Farhad Ravandi, Meghan Collins, Maria Emilia Di Francesco, Ecaterina E. Dumbrava, Siqing Fu, Sisi Gao, Jason Gay, Sonal Gera, Jing Han, David S. Hong, Elias Jabbour, Zhenlin Ju, Daniel D. Karp, Alessia Lodi, Jennifer R. Molina, Natalia Baran, Aung Naing, Maro Ohanian, Shubham Pant, Naveen Pemmaraju, Prithviraj Bose, Sarina A. Piha‐Paul, Jordi Rodón, Carolina Salguero, Koji Sasaki, Anand Kumar Singh, Vivek Subbiah, Apostolia M. Tsimberidou, Quanyun A. Xu, Musa Yılmaz, Qi Zhang, Yuan Li, Christopher A. Bristow, Meenakshi B. Bhattacharjee, Stefano Tiziani, Timothy P. Heffernan, Christopher P. Vellano, Philip Jones, Cobi J. Heijnen, Annemieke Kavelaars, Joseph R. Marszalek, Marina Konopleva - Nature Medicine 2023 被引用: 377

  3. Development of Immunotherapy Combination Strategies in Cancer

    著者: Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran, Hussein A. Tawbi - Cancer Discovery 2021 被引用: 320

  4. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    著者: Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono - New England Journal of Medicine 2009 被引用: 3,632

  5. Targeting the PI3K pathway in cancer: are we making headway?

    著者: Filip Jankú, Timothy A. Yap, Funda Meric‐Bernstam - Nature Reviews Clinical Oncology 2018 被引用: 1,032

  6. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

    著者: Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A. Yap, Gordon B. Mills, Guang Peng - Cancer Research 2018 被引用: 592

  7. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

    著者: Alexis Tabah, Niccolò Buetti, Quentin Staiquly, Stéphane Ruckly, Murat Akova, Abdullah Tarık Aslan, Marc Léone, Andrew Conway Morris, Matteo Bassetti, Kostoula Arvaniti, Jeffrey Lipman, Ricard Ferrer, Haibo Qiu, José-Artur Paiva, Pedro Póvoa, Liesbet De Bus, Jan J. De Waele, Farid Zand, Mohan Gurjar, Adel Alsisi, Khalid Abidi, Hendrik Bracht, Yoshiro Hayashi, Kyeongman Jeon, Muhammed Elhadi, François Barbier, Jean‐François Timsit, on behalf of the EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network, Alexis Tabah, Hamish Pollock, Ben Margetts, Meredith Young, Neeraj Bhadange, Steven Tyler, Anne Ledtischke, Mackenzie Finnis, Anne Ledtischke, Mackenzie Finnis, Jyotsna Dwivedi, Manoj Saxena, Vishwanath Biradar, Natalie Soar, Vineet Sarode, David Brewster, Adrian Regli, Elizabeth Weeda, Samiul Parvez Ahmed, Cheryl Fourie, Kevin B. Laupland, Mahesh Ramanan, James Walsham, Jason Meyer, Edward Litton, Anna Maria Palermo, Timothy A. Yap, Ege Eroglu, Antony Attokaran, C’havala Jaramillo, Khalid Mahmood Khan Nafees, Nurhikmahtul Aqilah Haji Abd Rashid, Haji Adi Muhamad Ibnu Walid, Tomas Mon, P. Dhakshina Moorthi, Shah Sudhirchandra, Dhadappa Damodar Sridharan, Qiu Haibo, Jianfeng Xie, Lu Wei-Hua, Zhen Wang, Chuanyun Qian, Jili Luo, Xiaomei Chen, Hao Wang, Peng Zhao, Juan Zhao, Qiu Wusi, Chen Mingmin, Lei Xu, Chengfen Yin, Ruilan Wang, Jinfeng Wang, Yongjie Yin, Min Zhang, Jilu Ye, Chungfang Hu, Suming Zhou, Min Huang, Jing Yan, Yan Wang, Bingyu Qin, Ling Ye, Xie Weifeng, Li Peije, Nan Geng, Yoshiro Hayashi, Toshiyuki Karumai, Masaki Yamasaki, Satoru Hashimoto, Koji Hosokawa, Junichiro Makino ほか 615 名 - Intensive Care Medicine 2023 被引用: 246

  8. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

    著者: Timothy A. Yap, David S.P. Tan, Angelika Terbuch, Reece Caldwell, Christina Guo, Boon Cher Goh, Valerie Heong, Noor R. Md. Haris, Saira Bashir, Yvette Drew, David S. Hong, Funda Meric‐Bernstam, Gary Wilkinson, Joseph Hreiki, Antje M. Wengner, Friedhelm Bladt, Andreas Schlicker, Matthias Ludwig, Yinghui Zhou, Li Liu, Sonal Bordia, Ruth Plummer, Eleni Lagkadinou, Johann S. de Bono - Cancer Discovery 2020 被引用: 256

  9. PARP inhibitors: enhancing efficacy through rational combinations

    著者: Deepak Bhamidipati, Jaime Haro-Silerio, Timothy A. Yap, Natalie Y.L. Ngoi - British Journal of Cancer 2023 被引用: 153

  10. Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance

    著者: Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew Tutt, Christopher J. Lord - Cancer Discovery 2020 被引用: 184

  11. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

    著者: Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee, David R. Spigel, Martin Højgaard, Stéphanie Lheureux, Niharika B. Mettu, Benedito A. Carneiro, Louise Carter, Ruth Plummer, Gregory M. Coté, Funda Meric‐Bernstam, Joseph O’Connell, Joseph D. Schonhoft, Marisa J. Wainszelbaum, Adrian J. Fretland, Peter Manley, Yi Xu, Danielle Ulanet, Victoria Rimkunas, Mike Zinda, María Koehler, Ian M. Silverman, Jorge S. Reis‐Filho, Ezra Y. Rosen - Nature Medicine 2023 被引用: 102

  12. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

    著者: Jessica Brown, Brent O’Carrigan, Stephen P. Jackson, Timothy A. Yap - Cancer Discovery 2016 被引用: 629

  13. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

    著者: Timothy A. Yap, Brent O’Carrigan, Marina S. Penney, Joline S.J. Lim, Jessica Brown, Maria J. de Miguel, Nina Tunariu, Raquel Pérez-López, Daniel Nava Rodrigues, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Brian Hare, K. Mcdermott, Saira Khalique, Chris T. Williamson, Rachael Natrajan, Stephen J. Pettitt, Christopher J. Lord, Udai Banerji, John R. Pollard, Juanita Lopez, Johann S. de Bono - Journal of Clinical Oncology 2020 被引用: 248

  14. Antibody-drug conjugates in lung cancer: dawn of a new era?

    著者: Niamh Coleman, Timothy A. Yap, John V. Heymach, Funda Meric‐Bernstam, Xiuning Le - npj Precision Oncology 2023 被引用: 119

  15. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

    著者: Chaoyang Sun, Jun Yin, Yong Fang, Jian Chen, Kang Jin Jeong, Xiaohua Chen, Christopher P. Vellano, Zhenlin Ju, Wei Zhao, Dong Zhang, Yiling Lu, Funda Meric‐Bernstam, Timothy A. Yap, Maureen M. Hattersley, Mark J. O’Connor, Huawei Chen, Stephen E. Fawell, Shiaw‐Yih Lin, Guang Peng, Gordon B. Mills - Cancer Cell 2018 被引用: 302

  16. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors

    著者: Timothy A. Yap, Aditya Bardia, Michael Dvorkin, Matthew D. Galsky, J. Thaddeus Beck, David R. Wise, O. B. Karyakin, Gábor Rubovszky, Nikolay Kislov, Kristoffer Staal Rohrberg, Anil A. Joy, Melinda L. Telli, Alison M. Schram, Umberto Conte, Colombe Chappey, Ross Stewart, Daria Stypinski, Elisabete Michelon, Rossano Cesari, Panagiotis A. Konstantinopoulos - JAMA Oncology 2022 被引用: 100

  17. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

    著者: Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, Mark J. O’Connor, Timothy A. Yap - Clinical Cancer Research 2019 被引用: 332

  18. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

    著者: Yong Fang, Daniel J. McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P. Vellano, Yiling Lu, Yongsheng Li, Kang Jin Jeong, Zhiyong Ding, Jiyong Liang, Steven W. Wang, Hui Dai, Sanghoon Lee, Nidhi Sahni, Imelda Mercado‐Uribe, Tae-Beom Kim, Ken Chen, Shiaw‐Yih Lin, Guang Peng, Shannon N. Westin, Jinsong Liu, Mark J. O’Connor, Timothy A. Yap, Gordon B. Mills - Cancer Cell 2019 被引用: 241

  19. ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

    著者: Zhe Tang, Patrick G. Pilié, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Bradley M. Broom, Timothy C. Thompson - Clinical Cancer Research 2021 被引用: 142

  20. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    著者: Timothy A. Yap, Maria Vieito, Capucine Baldini, Juan Manuel Sepúlveda-Sánchez, Shunsuke Kondo, Matteo Simonelli, Rasha Cosman, Andre van der Westhuizen, Victoria Atkinson, Antoine F. Carpentier, Mario Löhr, Rebecca Redman, Warren Mason, Andres Cervantes, Emilie Le Rhun, Sebastian Ochsenreither, Louise Warren, Yumin Zhao, Sophie Callies, Shawn T. Estrem, Michael Man, Leena Gandhi, Emin Avsar, Davide Melisi - Clinical Cancer Research 2021 被引用: 74

  21. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    著者: Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye - Journal of Clinical Oncology 2010 被引用: 992

  22. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

    著者: Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, Adam W. Cook, Christina E. Wong, Ronald J. Hinklin, Yutong Jiang, Eric N. Brown, Nickolas A. Neitzel, Ellen R. Laird, Wen‐I Wu, Anurag Singh, Ping Wei, Keith A. Ching, John J. Gaudino, Patrice A. Lee, Dylan P. Hartley, S. Michael Rothenberg - Cancer Discovery 2023 被引用: 68

  23. Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations

    著者: Timothy A. Yap, David J. Kwiatkowski, Jayesh Desai, Ibiayi Dagogo‐Jack, Michael Millward, Hedy L. Kindler, Anthony W. Tolcher, Sophia Frentzas, Archie Thurston, Len Post, F Andrew Dorr - Cancer Research 2023 被引用: 64

  24. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer

    著者: Kurt W. Evans, Erkan Yuca, Stephen M. Scott, Ming Zhao, Natalia Paez Arango, Christian X. Cruz Pico, Turçin Saridogan, Maryam Shariati, Caleb A. Class, Christopher A. Bristow, Christopher P. Vellano, Xiaofeng Zheng, Ana M. González-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akçakanat, Bora Lim, Debu Tripathy, Timothy A. Yap, Maria Emilia Di Francesco, Giulio Draetta, Philip Jones, Timothy P. Heffernan, Joseph R. Marszalek, Funda Meric‐Bernstam - Cancer Research 2021 被引用: 157